Table 3.

The most common (≥ 10%) treatment-emergent adverse events by treatment arm

Adverse event	Etirinotecan pegol (n = 42)		Irinotecan (n = 41)
	No.	%	No.	%
Patients with ≥ 1 TEAE	42	100	41	100
Diarrhea	26	62	31	76
Nausea	23	55	24	59
Vomiting	18	43	21	51
Fatigue	20	48	18	44
Abdominal pain	18	43	14	34
Alopecia	7	17	24	59
Anorexia	13	31	10	24
Constipation	12	29	10	24
Weight decreased	13	31	6	15
Dehydration	6	14	8	20
Dizziness	7	17	7	17
Neutropeniaa	11	26	12	29
Hypokalemia	9	21	4	10
Anemia	6	14	6	15
Pyrexia	4	10	7	17
Asthenia	7	17	3	7
Upper abdominal pain	5	12	4	10
Decreased hemoglobin	2	5	6	15
Hyponatremia	5	12	3	7
Lethargy	3	7	5	12
Leukopenia	5	12	2	5
Abdominal distention	1	2	5	12
Headache	5	12	1	2
Blurred vision	5	12	1	2
Anxiety	5	12	0	0

TEAE treatment-emergent adverse events

^aIncludes neutropenia, decreased neutrophils, and febrile neutropenia